- Home
- BGSF vs MAIA Comparison
BGSF vs MAIA Comparison
Compare BGSF & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGSF
- MAIA
- Stock Information
- Founded
- BGSF 2007
- MAIA 2018
- Country
- BGSF United States
- MAIA United States
- Employees
- BGSF N/A
- MAIA N/A
- Industry
- BGSF Professional Services
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- BGSF Consumer Discretionary
- MAIA Health Care
- Exchange
- BGSF Nasdaq
- MAIA Nasdaq
- Market Cap
- BGSF 47.7M
- MAIA 46.7M
- IPO Year
- BGSF N/A
- MAIA 2022
- Fundamental
- Price
- BGSF $6.14
- MAIA $1.76
- Analyst Decision
- BGSF Strong Buy
- MAIA
- Analyst Count
- BGSF 1
- MAIA 0
- Target Price
- BGSF $9.00
- MAIA N/A
- AVG Volume (30 Days)
- BGSF 294.3K
- MAIA 535.2K
- Earning Date
- BGSF 08-06-2025
- MAIA 08-08-2025
- Dividend Yield
- BGSF N/A
- MAIA N/A
- EPS Growth
- BGSF N/A
- MAIA N/A
- EPS
- BGSF N/A
- MAIA N/A
- Revenue
- BGSF $266,968,000.00
- MAIA N/A
- Revenue This Year
- BGSF N/A
- MAIA N/A
- Revenue Next Year
- BGSF N/A
- MAIA N/A
- P/E Ratio
- BGSF N/A
- MAIA N/A
- Revenue Growth
- BGSF N/A
- MAIA N/A
- 52 Week Low
- BGSF $2.91
- MAIA $1.40
- 52 Week High
- BGSF $9.06
- MAIA $4.24
- Technical
- Relative Strength Index (RSI)
- BGSF 54.26
- MAIA 56.41
- Support Level
- BGSF $6.30
- MAIA $1.80
- Resistance Level
- BGSF $7.65
- MAIA $2.15
- Average True Range (ATR)
- BGSF 0.51
- MAIA 0.13
- MACD
- BGSF -0.07
- MAIA 0.02
- Stochastic Oscillator
- BGSF 35.54
- MAIA 60.00
About BGSF BGSF Inc.
BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. two segments: Property Management and Professional. In the Property Management segment is a provider of office and maintenance talent. The Professional segment provides IT professionals with expertise in SAP, Workday, Peoplesoft, Hyperion, Oracle, One Stream, cyber, project management, managed services, and other IT workforce solutions to client partners on a national basis. The group generates the majority of its revenue from the Professional segment.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.